Sepracor-Looks very promising Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	6/1/2007 5:30:51 PM
	of 10280

Why Seprecor May Surprise The Naysayers Sentiment is mixed on Wall Street about Sepracor (SEPR ), the Marlborough (Mass.) pharmaceutical best known for its sleep drug, Lunesta. Launched in April, 2005, Sepracor had $567 million in revenues from the drug last year. This year the figure is expected to hit $685 million. In 2006 Sepracor saw its first year of operating profits--$185 million--and it has accumulated $1 billion in cash. But investors have been punishing the volatile stock, worried that Lunesta's market will be gnawed on by generic rivals. Then on May 21 the stock got hit by news that Medicare would cut reimbursement levels for its asthma drug, Xopenex, which accounts for half the company's total sales. The stock, at 49.07, is down more than 20% this year. Robert Hazlett of BMO Capital Markets (BMP ) says the gloom and doom are overdone and thinks the stock will hit 68 in 12 to 18 months. "This company is growing rapidly, and it's going to be more profitable than analysts estimate," he says. Lawrence Neibor of Robert W. Baird agrees. His 12-month target is 67. businessweek.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next